ストックスクリーナーアプリを入手
2.09
5.86%
-0.13
アフターアワーズ：
2.08
-0.010
-0.48%
前日終値:
$2.22
開ける：
$2.19
24時間の取引高:
31,808
Relative Volume:
0.62
時価総額：
$23.38M
収益：
-
当期純損益:
$-18.92M
株価収益率:
-1.1924
EPS:
-1.7527
ネットキャッシュフロー:
$-16.86M
1週間 パフォーマンス:
-3.24%
1か月 パフォーマンス:
-26.41%
6か月 パフォーマンス:
-53.09%
1年 パフォーマンス:
-42.74%
1日の値動き範囲:
$2.06
$2.19
1週間の範囲:
$2.03
$2.4098
52週間の値動き範囲:
$2.03
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Compare LTRN vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.09 | 24.83M | 0 | -18.92M | -16.86M | -1.7527 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-07 | 開始されました | H.C. Wainwright | Buy |
Lantern Pharma Inc (LTRN) 最新ニュース
Earnings Recap: Whats the beta of Lantern Pharma Inc stock2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET - BioSpace
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March - PharmiWeb.com
Lantern Pharma Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Lantern Pharma Showcases RADR AI: 70%-80% Faster Drug-to-Clinic Push, 12 FDA Designations - Defense World
Activity Recap: Whats the beta of Lantern Pharma Inc stock2026 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
LTRN: AI-driven innovation is transforming oncology drug development, with key catalysts ahead - TradingView
LTRN: AI-driven drug development yields rapid clinical progress, FDA designations, and new monetization paths - TradingView
Lantern Pharma (LTRN) to Release Earnings on Thursday - Defense World
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - Quantisnow
Lantern Pharma (LTRN) Stock Forecast and Price Target 2026 $LTRN - MarketBeat
Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - MSN
Lantern Pharma (LTRN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Institution Moves: What are Lantern Pharma Incs recent SEC filings showing2025 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
What are Lantern Pharma Inc.’s recent SEC filings showingJuly 2025 Review & High Accuracy Trade Alerts - mfd.ru
LTRN Should I Buy - Intellectia AI
Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday - Defense World
LTRN Technical Analysis & ETF Price Forecast - Intellectia AI
Bull Run: What is Lantern Pharma Incs P E ratio telling usWeekly Market Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
LTRN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bios group controls 8.58% of Lantern Pharma (LTRN) common stock - Stock Titan
LTRN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Bitget
Aug Gainers: Can Lantern Pharma Inc. stock sustain institutional interestMarket Trend Report & Weekly High Potential Stock Alerts - mfd.ru
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Asheville Citizen Times
Growth Report: How much upside does GWRE haveMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Patterns Watch: Is Lantern Pharma Inc stock undervalued right nowJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Corpus Christi Caller-Times
Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform - Digital Health News
FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas - Investing.com Nigeria
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - PharmiWeb.com
Lantern Pharma (LTRN) Secures Orphan Drug Designation for LP-284 - GuruFocus
Lantern Pharma Establishes New AI Centre Of Excellence, Agentic Labs Hub In Bengaluru - Voice Of HealthCare
Lantern Pharma Expands Global AI Footprint with Bengaluru Center of Excellence - eHealth Magazine
Critical Comparison: Lantern Pharma (NASDAQ:LTRN) versus Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
FDA Grants Orphan Drug Status to Lantern Pharma's Treatment for Sarcoma (LTRN) - GuruFocus
Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally - Indian Pharma Post
Recap Report: Whats the outlook for Lantern Pharma Incs sectorQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru - BioSpectrum India
History Review: Is Lantern Pharma Inc stock a hidden gemGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RAD - PharmiWeb.com
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - 01net
Lantern Pharma IncEstablishes Ai Center Of Excellence In Bengaluru - TradingView — Track All Markets
Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - Улправда
Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - Улправда
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc (LTRN) 財務データ
収益
当期純利益
現金流量
EPS
0.04%
0.06%
大文字化:
|
ボリューム (24 時間):